2025 RESEARCH FAST FACTS

# Research Programs Overview

## RESEARCH GRANT INVESTMENT AT A GLANCE:
(1982-2025)

Nearly **$1.1 billion** in more than **2,800** research grants & more than **600** clinical trials

## ABOUT OUR RESEARCH PROGRAMS

Despite successes in awareness and progress in diagnosis and treatment, breast cancer remains a devastating disease. Nearly 43,000 breast cancer deaths are predicted this year in the U.S. alone. Komen believes the future of breast cancer treatment, diagnosis and prevention will come from breakthrough research on the most deadly and aggressive forms of breast cancer and solving the causes of breast cancer health disparities. Our focus remains to advance precision medicine (personalized medicine), improve health outcomes for everyone and to train the next generation of cancer researchers. Through breast cancer research and clinical trials, we're driving progress toward a brighter future: a world without breast cancer.

## WHAT WE'RE INVESTIGATING

- Using tumor registry data to investigate how factors like race, genetics and the body's immune system affect breast cancer outcomes and using those findings to improve treatments and make clinical trials more inclusive.
- Using cancer tissue samples to find new targets for therapies that can be developed for treatment people with breast cancer that has spread to the brain.
- Studying proteins that may cause breast cancers to form with the goal to find new targets for breast cancer prevention and treatment.

## IN THE KOMEN RESEARCH PIPELINE (1982-2025):

More than **4,200** new breast cancer **research discoveries** (drugs, biomarkers, devices, etc.)

More than **2,400** discoveries to advance **precision medicine** including **1,800** potential treatments.

Over **1,500** discoveries focused on metastatic and other deadly and aggressive breast cancers, with nearly **900** focused on potential treatments.

Over **600** new discoveries focused on strategies to reduce breast cancer **disparities & inequities**.

## SPOTLIGHT

Our research investments are guided by more than 50 leading scientists and advocates, including our Scientific Advisory Board, Komen Scholars and Advocates in Science. As a global leader in the fight against breast cancer, we have funded research in 47 states, DC, and Puerto Rico, as well as and 24 different countries. Our commitment to the most promising, innovative, and meaningful breast cancer research will never waver. Read more about Komen's research impact here.



## WHAT WE'VE LEARNED FROM KOMEN-FUNDED RESEARCH

- A new tumor genomic test may help people with early-stage HER2+ breast cancer and their doctors make better treatment decisions.
- A recent large-scale study reported that an artificial intelligence (AI) model may be more consistent with the evaluation of breast density than evaluation by radiologists, supporting utility of AI in breast density evaluation for breast clinical care.
- Living in disadvantaged neighborhoods was associated with poor breast cancer outcomes for some Black women in the U.S. regardless of stage at diagnosis, treatments and lifestyle factors, highlighting the importance of improving conditions in these neighborhoods to improve breast cancer outcomes.

**LEARN MORE ABOUT BREAST CANCER** | **MORE KOMEN-FUNDED RESEARCH STORIES** | **GET INVOLVED & SUPPORT RESEARCH**